NaviFUS Corp.
Our Vision
NaviFUS is a Biotech company dedicated to providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Our product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes.
Our vision is to benefit CNS disease patients locally and globally by bringing breakthrough therapeutic ultrasound technology to clinical use through partnerships with global pharmaceutical companies.
Our History
NaviFUS Corp. was founded in 2015 , culminating from years of novel academic research by Dr. Hao-Li Liu in ultrasound technology at the Department of Electrical Engineering of Chang Gung University in Taiwan. Since then, the company has teamed up with local hospitals and other experts in biomedical, medical device, pharmaceutical, and regulatory domain to conduct clinical trials for the treatment of brain tumors and epilepsy in Taiwan. In 2018, the company also co-invested with Genovate Biotechnology Co., Ltd. for setting up a subsidiary company in Australia, where a clinical trial for focused ultrasound therapy in Epilepsy is ongoing.
NaviFUS | Curing disease with sound
Our Management Team
Jen Chen, Ph.D
Chairman of the Board
Dr. Chen has over 30 years of new drug discovery and development experience, holding previous positions at Novartis and Genelabs. He founded Genovate Biotech in Taiwan and launched its IPO as an over the counter (OTC) company. Dr. Chen also currently presides over other public and OTC biotech companies in Taiwan, with the vision of elevating Taiwan’s footprint in the global biotechnology industry.
Arthur Lung, Ph.D.
Chief Executive Officer
Dr. Lung holds MSc and PhD degrees in Biomechanics from the University of Wisconsin-Madison and National Yang-Ming University, respectively. He has over 25 years of medical device product design, development, marketing, and selling experience, which has translated into 24 product launches during his career at United Orthopedic and Medtronic. He also has extensive entrepreneurship experience in the healthcare industry.
Hao-Li Liu, Ph.D.
Founder & Chief Technical Consultant
Dr. Liu completed his post-doctoral training at Harvard University and is the Chief Technology Consultant at NaviFUS. He is also a Distinguished Professor in the Department of Electrical Engineering at National Taiwan University. He has published more than 130 science citation index papers and has filed over 30 patents for biomedical uses of therapeutic ultrasound. He is the primary architect behind the NaviFUS system and its uses in central nervous system (CNS) diseases.
Our Values
Coming together is a beginning staying together is progress, and working together is a success.
Collaboration
We achieve more by working together. We strive for successful collaborative relationships with our team, our partners, our peers, and our customers, ensuring we use our technology and knowledge to benefits people.
Innovation
Good is never enough; We are always seeking newer and better ways. We continuously innovate to improve our understanding of complex diseases and find new innovate treatment solutions that benefit patients.
Integrity
We always do the right thing and not the easy thing. We adhere to high standards of professional values and practices in all our projects to ensure the safety and quality results are paramount to us.
Company Milestones
$ 48M USD
Total market volume
8+ trials
Clinical trials (Ongoing and complete)
37+ Countries
Patents globally
2009–2017
From academic R&D to startup foundation — Series A1 (USD 6M)
2009–2015: Chang Gung University R&D supported by major government-funded projects.
2015.03: NaviFUS Corp. founded in Taiwan with funding from angel investors.
2015.12: NaviFUS System won the 12th National Innovation Award.
2016.07: Accepted as an “Actively-Guided Case” in TFDA consultation.
2016.07: Closed Series A1 funding of USD 6M from Taiwan venture capital and the pharmaceutical industry.
2017.12: NaviFUS System won the Future Tech Award.
2018–2019
Clinical validation in rGBM & Epilepsy — Series A2 (USD 7M)
2018.01: TFDA approved Phase 1 IDE clinical trial for rGBM.
2018.07: Secured Series A2 funding of USD 7M.
2018.11: Received “Fast Track Case” designation from the Center for Drug Evaluation (CDE).
2019.02: TFDA approved a Phase 1 Epilepsy clinical trial in Taiwan.
2019.06: Completed Phase 1 rGBM trial, demonstrating safe BBB opening and recovery.
2019.08: Won the 2019 Taipei Biotech Awards.
2020–2021
Combination therapy expansion — Series A3 (USD 5.3M) & A4 (USD 10M)
2020.03: TFDA approved FUS + bevacizumab clinical trial.
2020.08: Approved for use in an Alzheimer’s disease clinical trial in Australia.
2020.09: Launched FUS + bevacizumab trial to test combination therapy efficacy in rGBM.
2020.12: Closed Series A3 funding of USD 5.3M.
2021.08: Approved for FUS + re-irradiation (re-RT) clinical trial; closed Series A4 funding of USD 10M.
2021.09: Launched Phase II Epilepsy trial in Taiwan.
2022–2023
U.S. expansion, clinical progress & strategic partnerships — Series A5 fundraising
2022.03: U.S. FDA pilot IDE approved for rGBM at Stanford University.
2022.06: Listed on TPEx Emerging Stock Board.
2022.10: Strategic cooperation with Brainlab.
2023.09: Taiwan Phase II rGBM (FUS-BBB opening + Avastin) completed.
2023.10: Australia Epilepsy trial initiated.
2024
Pivotal trials & U.S. multi-site IDEs; SDT first patient; strategic partnership
2024.01: Approved as a technology-based enterprise for listing on TPEx.
2024.01: TFDA approved the pivotal FUS-BBB opening + Avastin rGBM clinical trial.
2024.02: U.S. FDA approved pilot IDE rGBM trial at University of Virginia.
2024.03: U.S. FDA approved pilot IDE epilepsy neuromodulation trial at Stanford, UVA, and Brigham and Women’s Hospital.
2024.03: First participant received FUS-Sonodynamic Therapy for glioblastoma in a new pilot clinical trial.
2024.04: NaviFUS and Bracco signed a cooperation agreement for FUS-microbubble studies.
2025
TPEx listing & clinical momentum in epilepsy; platform expansion
2025.03: Successfully listed on the Taipei Exchange (TPEx) (TPEX: 6872) on March 7, 2025.
2025.04: Australia drug-resistant epilepsy (DRE) clinical trial initiated (up to 18 participants in Melbourne).
2025.08: U.S. multicenter DRE trial treated its first patient (mid-August).
2025.11: Reported positive safety outcomes from Australia DRE Cohort 1 and presented encouraging early stroke rehabilitation data at AOCCN 2025.
NaviFUS Awards
2014
Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards
Innovation Potential Award
2015
National Innovation Award
Academic Research Innovation category
2017
Future Technology Breakthrough Award
Winner
2019
Taipei Biotech Awards
Innovation Award
2022
Edison Awards
Gold Winner
2023
TIE Award
Honorable Mention
2024
TECO Award
Winner
NaviFUS Corp. is always open to collaborating with partners across the world.
Feel free to contact us with any questions regarding collaboration.